TOWA PHARMACEUTICAL CO.,LTD.

4553.TJapan

15 filed reports · 287 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

¥274B

FY2026 · to Mar 31, 2026

up +5.4% vs ¥260B

Half-year report

Net income

¥5.25B

FY2026 · to Mar 31, 2026

down −72.3% vs ¥19B

Annual report

Operating income

¥23.1B

FY2026 · to Mar 31, 2026

down −0.6% vs ¥23.2B

Annual report

Latest half year

Revenue

¥142B

H1 FY2027 · to Sep 30, 2026

up +9.0% vs ¥130B

Half-year report

Net income

¥6.87B

H1 FY2027 · to Sep 30, 2026

down −16.4% vs ¥8.21B

Half-year report

Operating income

¥12.7B

H1 FY2027 · to Sep 30, 2026

up +22.0% vs ¥10.4B

Half-year report

Filed reports

15 reports · Dec 2021 to Sep 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Annual · annual securities reportEDINET41,769Mar 2022 to Mar 2026
Half Year · half-year securities reportEDINET3751Sep 2024 to Sep 2026
Q3 · quarterly securities reportEDINET3532Dec 2021 to Dec 2023
Half Year · quarterly securities reportEDINET2429Sep 2022 to Sep 2023
Q1 · quarterly securities reportEDINET2372Jun 2022 to Jun 2023
Annual · amended annual securities reportEDINET1350Mar 2024

Documents

PeriodTypePeriod endPublishedFactsSource
FY2027 H1half-year securities report2026-09-302026-11-12316Open
FY2026annual securities report2026-03-312026-06-22723Open
FY2026 H1half-year securities report2025-09-302025-11-11220Open
FY2025annual securities report2025-03-312025-06-24348Open
FY2025 H1half-year securities report2024-09-302024-11-13215Open
FY2024amended annual securities report2024-03-312024-07-10350Open
FY2024 Q3quarterly securities report2023-12-312024-02-14218Open
FY2024 H1quarterly securities report2023-09-302023-11-14213Open
FY2024 Q1quarterly securities report2023-06-302023-08-10209Open
FY2023annual securities report2023-03-312023-06-28352Open
FY2023 Q3quarterly securities report2022-12-312023-02-14163Open
FY2023 H1quarterly securities report2022-09-302022-11-14216Open

Financial data

287 concepts · 4,203 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

GAAP274 concepts · 3,882 facts · Mar 2020 to Sep 2026

  • EPS (Basic)44 · Mar 2020 to Sep 2026
  • Equity-to-asset ratio, Key financial data37 · Mar 2020 to Sep 2026
  • Net Assets37 · Mar 2020 to Sep 2026
  • Ordinary profit (loss), Key financial data37 · Mar 2020 to Sep 2026
  • Revenue37 · Mar 2020 to Sep 2026
  • Total Assets37 · Mar 2020 to Sep 2026
  • Net assets, Key financial data34 · Mar 2020 to Sep 2026
  • Allowance for doubtful accounts-CA-by group32 · Mar 2021 to Sep 2026
  • Allowance for doubtful accounts-IOA-by group32 · Mar 2021 to Sep 2026
  • Capital surplus32 · Mar 2021 to Sep 2026
  • Cash and deposits32 · Mar 2021 to Sep 2026
  • Construction in progress32 · Mar 2021 to Sep 2026
  • Current portion of long-term borrowings32 · Mar 2021 to Sep 2026
  • Electronically recorded monetary claims - operating32 · Mar 2021 to Sep 2026
  • Electronically recorded obligations - operating32 · Mar 2021 to Sep 2026
  • Income taxes payable32 · Mar 2021 to Sep 2026
  • Intangible assets32 · Mar 2021 to Sep 2026
  • Investments and other assets32 · Mar 2021 to Sep 2026
  • Investment securities32 · Mar 2021 to Sep 2026
  • Land32 · Mar 2021 to Sep 2026
  • Long-term borrowings32 · Mar 2021 to Sep 2026
  • Merchandise and finished goods32 · Mar 2021 to Sep 2026
  • Other-CA32 · Mar 2021 to Sep 2026
  • Other-CL32 · Mar 2021 to Sep 2026

Segment13 concepts · 321 facts · Mar 2021 to Sep 2026

  • Operating Income72 · Mar 2021 to Sep 2026
  • Revenue65 · Mar 2021 to Sep 2026
  • Revenues from external customers54 · Mar 2021 to Sep 2026
  • Transactions with other segments33 · Dec 2022 to Sep 2026
  • Total Assets21 · Mar 2021 to Mar 2026
  • Depreciation, Segment Information18 · Mar 2021 to Mar 2026
  • Increase in property, plant and equipment and intangible assets18 · Mar 2021 to Mar 2026
  • Goodwill13 · Mar 2021 to Mar 2026
  • Amortization of goodwill-SGA12 · Mar 2021 to Mar 2026
  • Number of employees6 · Mar 2024 to Mar 2026
  • Research and development expenses, Research and development activities4 · Mar 2025 to Mar 2026
  • Average number of temporary employees3 · Mar 2024 to Mar 2026
  • Impairment losses - EL2 · Mar 2023 to Mar 2026

Segments

321 facts

Figures broken down by business line, region, product or another axis the company reports on.

Operating segments5 members · 321 facts

  • OverseasReportableSegmentsMember101 · Mar 2021 to Sep 2026
  • DomesticReportableSegmentsMember88 · Mar 2021 to Sep 2026
  • ReportableSegmentsMember87 · Mar 2021 to Sep 2026
  • ReconcilingItemsMember43 · Mar 2021 to Sep 2026
  • JapanReportableSegmentsMember2 · Mar 2025 to Mar 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of TOWA PHARMACEUTICAL CO.,LTD. (4553.T) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.

TOWA PHARMACEUTICAL CO.,LTD. (4553.T): FY2026 revenue ¥274B · FactIQ